je.st
news
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
enter
types
multiple
Category:Biotechnology and Pharmaceuticals